Steven R. Gerbsman, Principal of Gerbsman Partners and Kenneth Hardesty, a member of Gerbsman Partners Board of Intellectual Capital, are pleased to announce their success in maximizing stakeholder value for a technology company that provided comprehensive standards-based solutions for role-based access control (RBAC) across enterprise networks and a medical device company that focused on the development of innovative cardiac reshaping devices to treat functional mitral regurgitation (FMR) and left ventricular (LV) dysfunction, both of which are significant in the progression of congestive heart failure (CHF).

Gerbsman Partners provided Crisis Management and Investment Banking services, focused on the control, preservation and forecasting of CASH, stabilized the creditors, provided leadership to management and the Board of Directors and facilitated the sale of associated Intellectual Property and assets. Due to market conditions, these venture capital-backed companies and their senior lenders made the strategic decision to maximize the value of the business unit and Intellectual Property.

Gerbsman Partners provided leadership to the company with:

• Technology and Medical Device experience in developing the strategic action plans for maximizing value of the business unit, Intellectual Property and assets;
• Proven domain expertise in maximizing the value of the business unit and Intellectual Property through a targeted and proprietary Gerbsman Partners “Date Certain M&A" plan;
• The ability to "Manage the Process" among potential Acquirers, Lawyers, Creditors, Management, Board of Directors and Advisors;
• The proven ability to "Drive" toward successful closure for all parties at interest.

About Gerbsman Partners

Gerbsman Partners focuses on maximizing enterprise value for stakeholders and shareholders in under-performing, under-capitalized and under-valued companies and their Intellectual Property. In the past 60 months, Gerbsman Partners has been involved in maximizing value for 50 Technology, Life Science and Medical Device companies and their Intellectual Property and has restructured/terminated over $750 million of real estate executory contracts and equipment lease/sub-debt obligations. Since inception, Gerbsman Partners has been involved in over $2.2 billion of financings, restructurings and M&A transactions.

Gerbsman Partners has offices and strategic alliances in Boston, New York, Washington, DC, San Francisco, Europe and Israel.